Calithera Biosciences, Inc. (NASDAQ:CALA) represented a move of 0.35 percent or $-0.05 per share and closed its previous day trading session at $7.1. 567693 Shares were traded in the last trading session with an Average Volume of 621.17 Million Shares. The stock currently has a Market Capitalization of 243.25 Million.
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company’s lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California.
The stock traded between $ 6.57 and $20.05 over 1-Year time period showing its price to sales ratio of 13.01. Calithera Biosciences, Inc. (NASDAQ:CALA) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-15.23 and 200-Day Simple Moving Average of $-46.88. Its Price to Free Cash Flow is 15.69 and Price to Book of 1.59.
Analyst’s recommended the stock as 1.6 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Calithera Biosciences, Inc. (NASDAQ:CALA) reported its Actual EPS of $-0.17/share. The analysts offering Earnings Estimates for the company were believing that Calithera Biosciences, Inc. could bring EPS of $-0.22/share. The difference between Actual EPS and Estimated EPS was 0.05 Percent. Thus showing an Earnings Surprise of 22.7 Percent.
Coherus Biosciences, Inc. (NASDAQ:CHRS)
In the last trading session, Coherus Biosciences, Inc. (NASDAQ:CHRS) added its value by 1.55% closing at the price of $9.8. The stock currently has market capitalization of 564.87 Million, with average volume of 633.93 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Coherus Biosciences, Inc. (NASDAQ:CHRS) is showing beta of 0. This particular value of beta suggests that Coherus Biosciences, Inc. (NASDAQ:CHRS) has historically moved 0% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Coherus Biosciences, Inc. (NASDAQ:CHRS) is at $-5.42.
The stock currently has RSI of 44.47. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.
Coherus Biosciences, Inc. (NASDAQ:CHRS) topped its 52-week high price of $26.55 on 03/02/17 and 52-Week Low Price of $ 8.05 on 11/20/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.25% and monthly volatility of 7.68% respectively.